Best supportive care in lung cancer trials is inadequately described: A systematic review

European Journal of Cancer Care

Volumn 19, Issue 3, 2010, Pages 293-301

  Jack, B ^a   Boland, A ^a   Dickson, R ^b   Stevenson, J ^c   Mcleod, C ^b  

^a EDGE HILL UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Marie Curie Palliative Care Institute   (United Kingdom)

Author keywords

Best supportive care; Lung cancer trials

Indexed keywords

ARTICLE; HUMAN; LUNG TUMOR; METHODOLOGY; NOMENCLATURE; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TERMINOLOGY AS TOPIC;

EID: 77953162083     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2008.01064.x     Document Type: Article

References (44)

1. Ahmed N, Ahmedzai SH, Vora V, Hillam S, Paz S. Supportive care for patients with gastrointestinal cancer. The Cochrane Database of Systematic Reviews 2004, Issue 3
2. Alberti W, Anderson G, Bartolucci A, Bell D, Villalba JB, Brodin O, Cardiello C, Cartei F, Cartei G, Cellerino R, Chastang C, Cormier Y, Cox JD, Crino L, Crowley J, Dautzenberg B, Depierre A, Dietemann A, Dillman RO, Doi O, Feld R, Figlin R, Ganz PA, Green MR, Gregor A, Helle PA, Herndon JE, Hitomi S, Host H, Imaizumi M, Jett JR, Johnson D, Kaasa S, Kimura H, Klastersky J, Kondo H, Kreisman H, Kris MG, Kunishima K, Kuwahara O, Lad TE, Laing AH, Macbeth F, Masaoka A, Mattson K, Minatel E, Mira JG, Mori T, Mountain CF, Niederle N, Niiranen A, Nou E, Page W, Pater J, Piantadosi S, Pisters KMW, Pyrhonen S, Quoix E, Rapp E, Rowell NP, Sahmoud T, Sawamura K, Schallier DCC, Scott C, Simpson J, Stagg M, Teramatsu T, Trovo MG, Tsuchiya R, Tummarello D, Vanhoutte P, Vanzandwijk N, Vincent RG, Wada H, White JE, Williams CJ, Woods RL, Yamaguchi Y, Arriagada R, Cartmelldavies J, Girling DJ, Lechevalier T, Marsoni S, Parmar MKB, Pignon JP, Rekacewicz C, Souhami RL, Stewart LA, Tarayre M, Tinazzi A, Toni V. Chemotherapy in non-small-cell lung-cancer - a metaanalysis using updated data on individual patients from 52 randomized clinical-trials. British Medical Journal 1995, 311:899-909.
3. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J. Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. British Journal of Cancer 2000, 83:447-453.
4. Bonfill X, Serra C, Sacristan M, Nogue M, Losa F, Montesinos J. Second-line chemotherapy for non-small cell lung cancer. The Cochrane Database of Systematic Reviews 2001, Issue 4
5. Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MKB, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. Journal of Clinical Oncology 2005, 23:7417-7427.
6. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, MacNeil M, Palmer M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. Journal of Clinical Oncology 2005, 23:6674-6681.
7. Cancer Statistics. 2007, http://info.cancerresearchuk.org/cancerstats/types/lung, Cancer Research UK, Available at: (accessed 5/7/2007
8. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005, 50:355-374.
9. Clerici M, Frontini L, Ianniello GP, Maiorino L, Piantedosi FV, Cigolari S, Manzione L, Failla G, Zuccarino L, Pedicini T, Vinante O, Castiglione F, Bearz A, Tonato M, Rossi A, Monfardini S, Gallo C, Perrone F, Gridelli C. Vinorelbine plus best supportive care (BSC) vs. BSC in the treatment of advanced non small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial. Annals of Oncology 1998, 9:62-62.
10. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. [see comment. Journal of Clinical Oncology 1999, 17:3188-3194.
11. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004, 43:183-194.
12. De Marinis F, Rinaldi M, Ardizzoni A, Bruzzi P, Pennucci MC, Portalone L, D'Aprile M, Ripanti P, Romano F, Belli M, Altavilla G, Migliorino MR, Rosso R, Salvati F. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force. Tumori 1999, 85:177-182.
13. Dooms CA, Vansteenkiste JF. Treatment of patients with advanced non-small cell lung cancer. American Journal of Cancer 2004, 3:281-290.
14. Gralla RJ, Shepherd FA, Kim YP, Bizarri JP. Docetaxel versus supportive care in previously treated patients with non-small cell lung cancer (NSCLC): analysis of quality of life and clinical benefit parameters in a randomized trial. Lung Cancer 2000, 29(1):S276. Suppl.
15. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001, 6(1):4-7. Suppl.
16. Gridelli C, Ianniello GP, Maiorino L, Piantedosi V, Cigolari S, Manzione L, Failla G, Zuccarino L, Pedicini T, Vinante O, Castiglione F, Clerici M, Bearz A, Darwish S, Rossi A, Monfardini S, Gallo C, Perrone F, Frontini L. Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial. Annals of Oncology 1998, 9(Suppl. 4):85-85.
17. Gridelli C, Perrone F, Gallo C, Rossi A, Scognamiglio F, Monfardini S, Ianniello GP, Tinessa V, Caprio MG, Santoro A, Maiorino L, Santoro M, Brancaccio L, Crispino C, Cigolari S, Di Lanno M, Angelini V, Manzione L, Bilancia D, Dinota A, Failla G, Aiello RA, Tralongo P, Figoli F, Zuccarino L, Pedicini T, Febbraro A, Zollo C, Frontini L, Zonato S, Azzarello G, Vinante O, Castiglione F, Porcile G, Bearz A, Sorio R, Tonato M, Darwish S, Veltri E, D'aprile M, Curcio C, Vasta M, Clerici M, Luporini G, Farris A, Alicicco MG, Bretti S, Bumma C, Ionta MT, Massidda B, Adamo V, Altavilla G, Stefani M, Michetti G, Iaffaioli RV, Marzano N, Favaretto A, Murtas S, Nascimbene C, Nistico C, Robbiati SF, Strada MR, Belli M, Loizzi M, Bandera M, Bochicchio AM, Piazza E, Foladore S, Giura R, Gualtieri G, Barni S, Cariello A, Mattioli R, Pazzola A, Gioga G, Puxeddu G, Bartolucci R, Graiff C, Del Conte G, Farriniello GA, Mauri F, Corradini GM, Capuano MA, Carrozza F, Gianni W. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute 1999, 91:66-72.
18. Hansen HH. Is there a role for chemotherapy of non-small cell lung cancer? Annals of Oncology 1995, 6(1):S79-S82. Suppl.
19. Helsing M, Bergman B. Chemotherapy with carboplatin and etoposide improves quality of life and survival in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 1997, 19:8-9.
20. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. European Journal of Cancer 1998, 34:1036-1044.
21. Hopwood P, Anderson H, Stephens RJ, Thatcher N. Quality of life (QL) as a primary outcome in a randomised trial of palliative chemotherapy in non-small cell lung cancer (NSCLC). Supportive Care in Cancer 1999, 172(7). Suppl., abstract no. 0-29
22. Khan KS, Kunz R, Kleijnen J, Antes G. Systematic Reviews to Support Evidence-based Medicine. How to Review and Apply Findings of Healthcare Research 2003, Royal Society of Medicine Press, London, UK
23. Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer 2001, 34(4):S95-S101. Suppl.
24. Medley L, Cullen M. Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer. Current Opinion in Oncology 2002, 14:384-388.
25. Definitions of Supportive and Palliative Care 2002, National Council for Hospice and Specialist Palliative Care Services (NCHSPCS), Briefing paper 11, National Council for Hospice and Specialist Palliative Care Services, London, UK
26. Improving Supportive and Palliative Care for Adults with Cancer: the Manual 2004, National Institute for Health and Clinical Excellence (NICE), Vol. 2006, National Institute for Health and Clinical Excellence, London, UK
27. Nicum S, Cullen MH. Chemotherapy versus palliative care in non-small cell lung cancer. Anti-Cancer Drugs 2000, 11:603-607.
28. Paesmans M. Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer. Current Opinion in Oncology 2002, 14:389-393.
29. Pallares C, Maroto P, Andres L, Gomez-Segura G, Huidobro G, Valenti V. Relationship between quality of life (QL) and clinical outcome in advanced non-small cell lung cancer (NSCLC): prospective randomized trial of best supportive care (BSC) vs. BSC plus chemotherapy (CT). Annals of Oncology 1996, 7(5):89. Suppl.
30. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute 2000, 92:1074-1080.
31. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R, Berille J. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000, 27:145-157.
32. Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? Journal of Clinical Oncology 2004, 22:1966-1974.
33. Shepherd FA, Gralla R, Ramlau R, Mattson K, Bergman B, Kraszko P, Rudd R, Berille J, Kim Y, Coughllin S. Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. European Journal of Cancer 1999, 35(4):247. Suppl., Abstract #979
34. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology 2000, 18:2095-2103.
35. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongpasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Beziak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine 2005, 353:123-132.
36. Sorenson S, Glimelius B, Nygren P, Care S. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncologica 2001, 40:327-339.
37. Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MKB, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004, 59:828-836.
38. Stephens R. Quality of life issues in non-small cell lung cancer. Expert Review of Pharmacoeconomics and Outcomes Research 2004, 4:215-226.
39. Stephens R, Gower NH, Napp V, Rudd RM, Spiro SC, Thorpe H. The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting abstract. 2002, European Respiratory Society Annual Congress 2002
40. Thatcher N, Ranson M, Anderson H, Burt P, Davidson N, Nicolson M, Falk S, Carmichael J, Washington T, Jeynes A. Phase III study of paclitaxel (Taxol (R)) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC). Annals of Oncology 1998, 9:1.
41. Thatcher N, Chang A, Parikh P, Pemberton K, Archer V. ISEL: a Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 2005a, 49(4). Suppl., abstract no. Pr4
42. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). [see comment. Lancet 2005b, 366:1527-1537.
43. Thongprasert S. Lung cancer and quality of life. Australia and New Zealand Journal of Medicine 1998, 28:397-399.
44. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung cancer (Amsterdam, Netherlands) 1999, 24:17-24.